MRK Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 23.96% compared to Merck &'s net margin of 23.56%. Merck &'s return on equity of 40.25% beat Gilead Sciences's return on equity of 2.5%.

Merck & has a consensus price target of $112.29, signalling upside risk potential of 18.73%. On the other hand Gilead Sciences has an analysts' consensus of $111.26 which suggests that it could fall by -0.16%. Given that Merck & has higher upside potential than Gilead Sciences, analysts believe Merck & is more attractive than Gilead Sciences.

Merck & has a beta of 0.348, which suggesting that the stock is 65.24% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.213, suggesting its less volatile than the S&P 500 by 78.702%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.3%. Gilead Sciences offers a yield of 2.78% to investors and pays a quarterly dividend of $0.79 per share. Merck & pays 45.8% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Merck & quarterly revenues are $15.6B, which are larger than Gilead Sciences quarterly revenues of $7.6B. Merck &'s net income of $3.7B is higher than Gilead Sciences's net income of $1.8B. Notably, Merck &'s price-to-earnings ratio is 14.05x while Gilead Sciences's PE ratio is 301.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.74x versus 4.87x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 23.96% compared to Merck &'s net margin of -117.16%. Merck &'s return on equity of 40.25% beat Moderna's return on equity of -29.09%.

Merck & has a consensus price target of $112.29, signalling upside risk potential of 18.73%. On the other hand Moderna has an analysts' consensus of $54.40 which suggests that it could grow by 57.13%. Given that Moderna has higher upside potential than Merck &, analysts believe Moderna is more attractive than Merck &.

Merck & has a beta of 0.348, which suggesting that the stock is 65.24% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.3%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & pays 45.8% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & quarterly revenues are $15.6B, which are larger than Moderna quarterly revenues of $956M. Merck &'s net income of $3.7B is higher than Moderna's net income of -$1.1B. Notably, Merck &'s price-to-earnings ratio is 14.05x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.74x versus 4.20x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 23.96% compared to Merck &'s net margin of 24.22%. Merck &'s return on equity of 40.25% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Merck & has a consensus price target of $112.29, signalling upside risk potential of 18.73%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 38.42%. Given that Regeneron Pharmaceuticals has higher upside potential than Merck &, analysts believe Regeneron Pharmaceuticals is more attractive than Merck &.

Merck & has a beta of 0.348, which suggesting that the stock is 65.24% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.3%. Regeneron Pharmaceuticals offers a yield of 0.13% to investors and pays a quarterly dividend of $0.88 per share. Merck & pays 45.8% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & quarterly revenues are $15.6B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Merck &'s net income of $3.7B is higher than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Merck &'s price-to-earnings ratio is 14.05x while Regeneron Pharmaceuticals's PE ratio is 17.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.74x versus 5.40x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 23.96% compared to Merck &'s net margin of --. Merck &'s return on equity of 40.25% beat Viking Therapeutics's return on equity of --.

Merck & has a consensus price target of $112.29, signalling upside risk potential of 18.73%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 221.44%. Given that Viking Therapeutics has higher upside potential than Merck &, analysts believe Viking Therapeutics is more attractive than Merck &.

Merck & has a beta of 0.348, which suggesting that the stock is 65.24% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.651%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.3%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & pays 45.8% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & quarterly revenues are $15.6B, which are larger than Viking Therapeutics quarterly revenues of --. Merck &'s net income of $3.7B is higher than Viking Therapeutics's net income of -$35.4M. Notably, Merck &'s price-to-earnings ratio is 14.05x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.74x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.